dextroamphetamine has been researched along with Parkinson Disease in 34 studies
Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.
(S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The appearance of dyskinetic movement disorders in humans following the chronic use of levodopa or amphetamine may be a manifestation of similarly increased dopamine receptor site sensitivity within the striatum." | 3.65 | Supersensitivity to d-amphetamine- and apomorphine-induced stereotyped behavior induced by chronic d-amphetamine administration. ( Crosset, P; Dana, N; Klawans, HL; Margolin, DI, 1975) |
| "This has not been assessed in a Parkinson's disease population." | 3.11 | Amphetamine-induced dopamine release and impulsivity in Parkinson's disease. ( Aumann, M; Claassen, DO; Donahue, MJ; Hay, KR; Kang, H; Song, AK; Stark, AJ; Trujillo, P; Yan, Y; Zald, DH, 2022) |
| " Our data suggest that chronic administration of intranasal deferoxamine may be a valid approach to limiting the mishandling of α-synuclein in the central nervous system observed in Parkinson's disease and slowing disease progression." | 1.39 | Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model. ( Andersen, KJ; Febbraro, F; Romero-Ramos, M; Sanchez-Guajardo, V; Tentillier, N, 2013) |
| "Bromocriptine (CB-154) is a direct-acting dopamine agonist of proven clinical efficacy in parkinsonism." | 1.26 | Bromocriptine-induced behavioral hypersensitivity: implications for the therapy of parkinsonism. ( Kanapa, DJ; Klawans, HL; Nausieda, PA; Weiner, WJ, 1978) |
| " Prolonged pretreatment with suprathreshold doses of amphetamine decreased the threshold dosage of both amphetamine and apomorphine necessary to elicit stereotyped behavior." | 1.25 | Effect of chronic amphetamine exposure on stereotyped behavior: implications for pathogenesis of l-dopa-induced dyskinesias. ( Crossett, P; Dana, N; Klawans, HL, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (52.94) | 18.7374 |
| 1990's | 5 (14.71) | 18.2507 |
| 2000's | 1 (2.94) | 29.6817 |
| 2010's | 7 (20.59) | 24.3611 |
| 2020's | 3 (8.82) | 2.80 |
| Authors | Studies |
|---|---|
| Mann, LG | 1 |
| Hay, KR | 2 |
| Song, AK | 2 |
| Errington, SP | 1 |
| Trujillo, P | 2 |
| Zald, DH | 2 |
| Yan, Y | 2 |
| Kang, H | 2 |
| Logan, GD | 1 |
| Claassen, DO | 2 |
| Aumann, M | 1 |
| Stark, AJ | 1 |
| Donahue, MJ | 1 |
| Lee, DW | 1 |
| Ryu, YK | 1 |
| Chang, DH | 1 |
| Park, HY | 1 |
| Go, J | 1 |
| Maeng, SY | 1 |
| Hwang, DY | 1 |
| Kim, BC | 1 |
| Lee, CH | 1 |
| Kim, KS | 1 |
| Frankl, JA | 1 |
| Bose, S | 1 |
| Kuo, PH | 1 |
| Fowler, E | 1 |
| Maderal, A | 1 |
| Yosipovitch, G | 1 |
| Febbraro, F | 1 |
| Andersen, KJ | 1 |
| Sanchez-Guajardo, V | 1 |
| Tentillier, N | 1 |
| Romero-Ramos, M | 1 |
| Stenslik, MJ | 1 |
| Potts, LF | 1 |
| Sonne, JW | 1 |
| Cass, WA | 1 |
| Turchan-Cholewo, J | 1 |
| Pomerleau, F | 1 |
| Huettl, P | 1 |
| Ai, Y | 1 |
| Gash, DM | 1 |
| Gerhardt, GA | 1 |
| Bradley, LH | 1 |
| Castro-Hernández, J | 1 |
| Adlard, PA | 1 |
| Finkelstein, DI | 1 |
| Christine, CW | 1 |
| Marks, WJ | 1 |
| Ostrem, JL | 1 |
| Zhang, LJ | 1 |
| Xue, YQ | 1 |
| Yang, C | 1 |
| Yang, WH | 1 |
| Chen, L | 1 |
| Zhang, QJ | 1 |
| Qu, TY | 1 |
| Huang, S | 1 |
| Zhao, LR | 1 |
| Wang, XM | 1 |
| Duan, WM | 1 |
| GILLINGHAM, FJ | 1 |
| KALYANARAMAN, S | 1 |
| Agrawal, AK | 1 |
| Shukla, S | 1 |
| Chaturvedi, RK | 1 |
| Seth, K | 1 |
| Srivastava, N | 1 |
| Ahmad, A | 1 |
| Seth, PK | 1 |
| Birkmayer, W | 1 |
| Riederer, P | 1 |
| Olsson, M | 1 |
| Nikkhah, G | 1 |
| Bentlage, C | 1 |
| Björklund, A | 2 |
| Borlongan, CV | 1 |
| Freeman, TB | 1 |
| Hauser, RA | 1 |
| Cahill, DW | 1 |
| Sanberg, PR | 1 |
| Menzaghi, F | 1 |
| Whelan, KT | 1 |
| Risbrough, VB | 1 |
| Rao, TS | 1 |
| Lloyd, GK | 1 |
| Hebb, MO | 1 |
| Robertson, HA | 1 |
| Diamond, BI | 1 |
| Borison, RL | 1 |
| Nausieda, PA | 1 |
| Weiner, WJ | 1 |
| Kanapa, DJ | 1 |
| Klawans, HL | 4 |
| David, J | 1 |
| Kaul, CL | 1 |
| Grewal, RS | 1 |
| Antelman, SM | 1 |
| Caggiula, AR | 1 |
| Costall, B | 1 |
| Naylor, RJ | 1 |
| Crossett, P | 1 |
| Dana, N | 2 |
| Margolin, DI | 1 |
| Crosset, P | 1 |
| Bhaskar, PA | 1 |
| Bhaskar, EA | 1 |
| Jagannathan, K | 1 |
| Ewing, SE | 1 |
| Weber, RJ | 1 |
| Zauner, A | 1 |
| Plunkett, RJ | 1 |
| Sonsalla, PK | 1 |
| Manzino, L | 1 |
| Heikkila, RE | 1 |
| Brundin, P | 1 |
| Nilsson, OG | 1 |
| Strecker, RE | 1 |
| Lindvall, O | 1 |
| Astedt, B | 1 |
| Snyder, SH | 1 |
| Wallach, MB | 1 |
| Gershon, S | 1 |
| Miller, E | 1 |
| Nieburg, HA | 1 |
| Ernst, AM | 1 |
| Dandiya, PC | 1 |
| Bhargava, LP | 1 |
2 reviews available for dextroamphetamine and Parkinson Disease
| Article | Year |
|---|---|
Putative neurotransmitters in the brain: selective neuronal uptake, subcellular localization, and interactions with centrally acting drugs.
Topics: Aminobutyrates; Amphetamine; Animals; Behavior; Brain; Brain Chemistry; Carbon Isotopes; Catecholami | 1970 |
The pharmacology of parkinsonism (a review).
Topics: Acetylcholine; Animals; Atropa belladonna; Atropine; Central Nervous System; Chlorpromazine; Dextroa | 1968 |
2 trials available for dextroamphetamine and Parkinson Disease
| Article | Year |
|---|---|
Amphetamine-induced dopamine release and impulsivity in Parkinson's disease.
Topics: Aged; Amphetamine; Autoreceptors; Dextroamphetamine; Dopamine; Humans; Impulsive Behavior; Ligands; | 2022 |
Cyclosporine-A increases locomotor activity in rats with 6-hydroxydopamine-induced hemiparkinsonism: relevance to neural transplantation.
Topics: Animals; Brain; Cyclosporine; Dextroamphetamine; Dopamine Agonists; Immunosuppressive Agents; Locomo | 1996 |
30 other studies available for dextroamphetamine and Parkinson Disease
| Article | Year |
|---|---|
D
Topics: Aged; Amygdala; Dextroamphetamine; Dopamine Uptake Inhibitors; Female; Hippocampus; Humans; Male; Mi | 2021 |
Topics: Animals; Base Composition; Clostridiales; Dextroamphetamine; Disease Models, Animal; Dopaminergic Ne | 2022 |
False-Positive Findings on Dopamine Transporter SPECT Due to Therapeutic Dextroamphetamine and Amphetamine.
Topics: Amphetamine; Dextroamphetamine; Dopamine Plasma Membrane Transport Proteins; False Positive Reaction | 2018 |
Treatment-induced Delusions of Infestation Associated with Increased Brain Dopamine Levels.
Topics: Aged; Attention Deficit Disorder with Hyperactivity; Brain; Deep Brain Stimulation; Delusional Paras | 2019 |
Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
Topics: Administration, Intranasal; alpha-Synuclein; Animals; Antigens, CD; Antigens, Differentiation, Myelo | 2013 |
Methodology and effects of repeated intranasal delivery of DNSP-11 in a rat model of Parkinson's disease.
Topics: Administration, Intranasal; Analysis of Variance; Animals; Antiparkinson Agents; Autoradiography; Co | 2015 |
Pramipexole restores depressed transmission in the ventral hippocampus following MPTP-lesion.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzothiazoles; Dextroamphetamine; Disease Mo | 2017 |
Development of Parkinson's disease in patients with Narcolepsy.
Topics: Adult; Age of Onset; Antiparkinson Agents; Cataplexy; Central Nervous System Stimulants; Deep Brain | 2012 |
Human albumin prevents 6-hydroxydopamine-induced loss of tyrosine hydroxylase in in vitro and in vivo.
Topics: Albumins; Animals; Caspase 3; Cell Line, Tumor; Dextroamphetamine; Disease Models, Animal; Dopaminer | 2012 |
PARKINSON'S DISEASE.
Topics: Amitriptyline; Dextroamphetamine; Humans; Imipramine; Muscle Relaxants, Central; Neurosurgery; Orphe | 1963 |
Olfactory ensheathing cell transplantation restores functional deficits in rat model of Parkinson's disease: a cotransplantation approach with fetal ventral mesencephalic cells.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain Tissue Transplantation; Cell Transp | 2004 |
Deprenyl prolongs the therapeutic efficacy of combined L-DOPA in Parkinson's disease.
Topics: Animals; Brain Chemistry; Dextroamphetamine; Drug Therapy, Combination; Female; Humans; Levodopa; Ma | 1984 |
Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Apomorphi | 1995 |
Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Corpus Striatum; Dextroamphetamine; Dopamine; Ion Channel | 1997 |
Motor effects and mapping of cerebral alterations in animal models of Parkinson's and Huntington's diseases.
Topics: Animals; Behavior, Animal; Brain; Brain Mapping; Corpus Striatum; Dextroamphetamine; Disease Models, | 1999 |
Enkephalins and nigrostriatal function.
Topics: Animals; Apomorphine; Behavior, Animal; Dextroamphetamine; Endorphins; Enkephalins; Hydroxydopamines | 1978 |
Bromocriptine-induced behavioral hypersensitivity: implications for the therapy of parkinsonism.
Topics: Animals; Apomorphine; Behavior; Bromocriptine; Dextroamphetamine; Guinea Pigs; Humans; Male; Parkins | 1978 |
Effect of intracaudate drug injections on the striatal syndrome in reserpinized cats.
Topics: Animals; Apomorphine; Atropine; Cats; Caudate Nucleus; Corpus Striatum; Dextroamphetamine; Disease M | 1977 |
Norepinephrine-dopamine interactions and behavior.
Topics: Aggression; Animals; Avoidance Learning; Behavior; Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulf | 1977 |
Neuropharmacological studies on D145 (1,3-dimethyl-5-aminoadamantan).
Topics: Amantadine; Animals; Apomorphine; Behavior; Corpus Striatum; Dextroamphetamine; Dopamine; Extrapyram | 1975 |
Effect of chronic amphetamine exposure on stereotyped behavior: implications for pathogenesis of l-dopa-induced dyskinesias.
Topics: Amphetamine; Animals; Apomorphine; Behavior; Corpus Striatum; Dextroamphetamine; Guinea Pigs; Humans | 1975 |
Supersensitivity to d-amphetamine- and apomorphine-induced stereotyped behavior induced by chronic d-amphetamine administration.
Topics: Animals; Apomorphine; Behavior; Corpus Striatum; Dextroamphetamine; Disease Models, Animal; Dopamine | 1975 |
Augmenting procedures during L-dopa therapy for Parkinsonism.
Topics: Antacids; Dextroamphetamine; Drug Synergism; Female; Humans; Imipramine; Levodopa; Male; Middle Aged | 1975 |
Recovery in hemiparkinsonian rats following intrastriatal implantation of activated leukocytes.
Topics: Animals; Caudate Nucleus; Corpus Striatum; Denervation; Dextroamphetamine; Ganglia, Spinal; Lectins; | 1992 |
Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Basal Ganglia; Benzazepines; Co | 1988 |
Behavioural effects of human fetal dopamine neurons grafted in a rat model of Parkinson's disease.
Topics: Animals; Catecholamines; Dextroamphetamine; Disease Models, Animal; Dopamine; Female; Fluorescent An | 1986 |
A neuropsychopharmacological comparison of d-amphetamine, L-dopa and cocaine.
Topics: Animals; Behavior, Animal; Cats; Cocaine; Cortical Synchronization; Dextroamphetamine; Dihydroxyphen | 1971 |
Amphetamines, valuable adjunct in treatment of Parkinsonism.
Topics: Aged; Amphetamine; Dextroamphetamine; Dihydroxyphenylalanine; Humans; Methylphenidate; Parkinson Dis | 1973 |
Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats.
Topics: Animals; Apomorphine; Chemistry, Pharmaceutical; Compulsive Behavior; Dextroamphetamine; Dihydroxyph | 1967 |
The antiparkinsonian activity of monoamine oxidase inhibitors and other agents in rats and mice.
Topics: Animals; Dextroamphetamine; Diphenhydramine; Imipramine; Iproniazid; Isocarboxazid; Mice; Monoamine | 1968 |